Citation tools
"A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-α Antagonist." The Journal of Rheumatology
(2014):
jrheum.140238.
Web. 19 April. 2024.